ATE478858T1 - Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind - Google Patents

Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind

Info

Publication number
ATE478858T1
ATE478858T1 AT07712220T AT07712220T ATE478858T1 AT E478858 T1 ATE478858 T1 AT E478858T1 AT 07712220 T AT07712220 T AT 07712220T AT 07712220 T AT07712220 T AT 07712220T AT E478858 T1 ATE478858 T1 AT E478858T1
Authority
AT
Austria
Prior art keywords
bace inhibitors
cyclic sulfones
sulfones suitable
medicaments
cyclic
Prior art date
Application number
AT07712220T
Other languages
English (en)
Inventor
Heinrich Rueeger
Clive Mccarthy
Henrik Moebitz
Jean-Michel Rondeau
Marina Tintelnot-Blomley
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE478858T1 publication Critical patent/ATE478858T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D335/00Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT07712220T 2006-02-14 2007-02-14 Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind ATE478858T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0602951.6A GB0602951D0 (en) 2006-02-14 2006-02-14 Organic Compounds
PCT/EP2007/051454 WO2007093621A1 (en) 2006-02-14 2007-02-14 Cyclic sulfones useful as bace inhibitors

Publications (1)

Publication Number Publication Date
ATE478858T1 true ATE478858T1 (de) 2010-09-15

Family

ID=36141810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07712220T ATE478858T1 (de) 2006-02-14 2007-02-14 Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind

Country Status (13)

Country Link
US (1) US20090099207A1 (de)
EP (1) EP1989194B1 (de)
JP (1) JP2009526820A (de)
KR (1) KR20080093049A (de)
CN (1) CN101384580A (de)
AT (1) ATE478858T1 (de)
AU (1) AU2007216463A1 (de)
BR (1) BRPI0707812A2 (de)
CA (1) CA2637857A1 (de)
DE (1) DE602007008691D1 (de)
GB (1) GB0602951D0 (de)
RU (1) RU2008136762A (de)
WO (1) WO2007093621A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2697254A1 (en) * 2007-08-23 2009-02-26 Novartis Ag Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
MX2011000390A (es) * 2008-07-10 2011-03-01 Novartis Ag Sulfonas ciclicas con sustitucion de amino-bencilo utiles coimo inhibidores de bace.
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
EP2485920B1 (de) 2009-10-08 2016-04-27 Merck Sharp & Dohme Corp. Heterozyklische pentafluorsulfur-imin-verbindungen als bace-1-hemmer sowie zusammensetzungen damit und ihre verwendung
EP2485591B1 (de) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Iminothiadiazindioxinverbindungen als bace-hemmer, zusammensetzungen und ihre verwendung
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
EP4471011B1 (de) * 2023-06-01 2026-01-14 Centre National de la Recherche Scientifique Verfahren zur selektiven spaltung von c-scf3-bindungen und analoga

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122091A1 (en) * 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
NZ538100A (en) * 2000-12-13 2006-07-28 Arqule Inc Heterocyclic sulfonamide inhibitors of beta amyloid production

Also Published As

Publication number Publication date
JP2009526820A (ja) 2009-07-23
EP1989194A1 (de) 2008-11-12
AU2007216463A1 (en) 2007-08-23
US20090099207A1 (en) 2009-04-16
GB0602951D0 (en) 2006-03-29
CN101384580A (zh) 2009-03-11
EP1989194B1 (de) 2010-08-25
KR20080093049A (ko) 2008-10-17
WO2007093621A1 (en) 2007-08-23
DE602007008691D1 (de) 2010-10-07
BRPI0707812A2 (pt) 2011-05-10
RU2008136762A (ru) 2010-03-20
CA2637857A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE478858T1 (de) Cyclische sulfone, die zur verwendung als bace- inhibitoren geeignet sind
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
CO6290714A2 (es) Compuestos organicos
EA200870116A1 (ru) Бициклические гетероарильные соединения
EA201170772A1 (ru) Органические соединения
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
DE112007001307A5 (de) Mikrobiologische Herstellung von 3-Hydroxyisobuttersäure
UA97834C2 (ru) Производные сульфониламида для лечения анормального роста клеток
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BRPI0908926A2 (pt) Compostos de policarbonato-poliorganosiloxano e/ou poliuretano-poliorganosiloxano
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
WO2007025709A3 (en) Organic compounds
EA201001639A1 (ru) Композиции и способы их получения и применения
DE602007007666D1 (de) Verfahren zur herstellung von nebivolol
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
CU20130063A7 (es) Proceso de producción de depsipéptidos cíclicos
MA32505B1 (fr) 5-alcynyl-pyrimidines
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
EA200870515A1 (ru) Моноциклические гетероарильные соединения
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
EA201101478A1 (ru) Композиции и способы модулирования связывания ретинола с ретинолсвязывающим белком 4 (rbp4)
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties